66th ASH Annual Meeting: 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Enhancing NK Cell Therapeutics

Symposia: Cellular Immunotherapies other than CAR-T Cells: Basic and Translational Oral and Poster Abstracts
Oral

Research, Fundamental Science, Combination therapy, Acute Myeloid Malignancies, AML, Translational Research, Drug development, Assays, Bispecific Antibody Therapy, Bioinformatics, Immune mechanism, Diseases, Cell expansion, Treatment Considerations, Biological therapies, Immunotherapy, Immunology, Biological Processes, Myeloid Malignancies, Technology and Procedures, Natural Killer (NK) Cell Therapies, Human, Omics technologies

Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina)

Moderators:

Caroline Arber, MD, ARRAY(0xed8d724) and May Daher, MD, MD, The University of Texas MD Anderson Cancer Center

Disclosures:

Arber: Immatics: Patents & Royalties.

For this session we have selected six top scoring abstracts for oral presentation that address key questions in the field of NK cell based cellular immunotherapies. These basic and translational abstracts develop novel tools, engineering or combinatorial drug strategies with the goal to improve responses against AML and other hematologic malignancies.

2:45 PM

913

Comprehensive Drug Profiling and CRISPR Screening Reveal Essential Pathways for NK Cell Cytotoxicity

Jonas Bouhlal, MSc, BSc^1,2,3^*, Emmi Jokinen^3,4,5^*, Petra Nygren^1,2,3^*, Diogo Dias, MSc^1,2,3,6^*, Aleksandr Ianevski⁶^*, Jay Klievink, M.Sc^2,3,5^*, Hanna Lähteenmäki, MSc^1,2,3^*, Essi Laajala, PhD^1,2,3^*, Hanna Duàn, MSc^1,2,3^*, Emmi Järvelä, MSc⁷^*, Helka Göös, PhD⁷^*, Matti Korhonen, MD, PhD^7,8^*, Salomé Decombis^1,3,9^*, Konstantin Matjusinski^1,2,3^*, Mikko Myllymäki, MD, PhD^1,2,3, Maija Hollmén¹⁰^*, Khalid Saeed, PhD^2,3^*, Dean Anthony Lee, MD, PhD¹¹, Tero Aittokallio, PhD^1,12,13,14^*, Sara Gandolfi, MD, PhD^1,2,3^*, Olli Dufva, MD, PhD^1,2,3,15^* and Satu Mustjoki, MD, PhD^2,3,16

¹iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland
²Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
³Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
⁴Hematology Research Unit Helsinki, Department of Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
⁵iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
⁶Institute For Molecular Medicine Finland (FIMM), Helsinki, Finland
⁷Finnish Red Cross Blood Service, Helsinki, Finland
⁸Helsinki University Central Hospital Hospital for Children and Adolescents, Helsinki, FIN
⁹Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital, Nantes, France
¹⁰MediCity Research Laboratory, Department of Microbiology and Immunology, University of Turku, Turku, Finland
¹¹Division of Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, OH
¹²Institute for Cancer Research, Department of Cancer Genetics, Oslo University Hospital, Oslo, Norway
¹³Centre for Biostatistics and Epidemiology (OCBE), Faculty of Medicine, University of Oslo, Oslo, Norway
¹⁴Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland
¹⁵Wellcome Sanger Institute, Hinxton, Cambridge, United Kingdom
¹⁶ICAN Digital Precision Cancer Medicine Flagship, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland

3:00 PM

914

A Novel Platform Technology for the Development of NK Cell-Based Cellular Immunotherapies

Ammelie Svea Boje¹^*, Anna Langner, PhD¹^*, Carina Lynn Gehlert, PhD¹^*, Carmen Reitinger, PhD²^*, Falk Nimmerjahn, PhD²^*, Eva Maria Murga Penas, PhD³^*, Sonja Bendig^4,5^*, Guranda Chitadze, MD, PhD^4,5^*, Monika Brüggemann, MD^5,6^*, Katharina Diemer, MD¹^*, Alexander Jochimsen¹^*, Dorothee Winterberg, PhD¹^*, Natalie Baum, PhD¹^*, Steffen Krohn¹^*, Thomas Valerius, MD^5,7^*, Friedrich Stölzel⁷^*, Martin Gramatzki, MD¹, Katja Klausz, PhD^1,5^*, Christian Kellner, PhD⁸^* and Matthias Peipp, PhD^1,5^*

¹Division of Antibody-Based Immunotherapy, Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
²Division of Genetics, Department of Biology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
³Institute for Human Genetics, Christian-Albrechts-University Kiel and University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany, Kiel, Germany
⁴Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany
⁵Clinical Research Unit CATCH ALL (KFO 5010/1) funded by the Deutsche Forschungsgemeinschaft, Kiel, Germany
⁶Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Kiel, Germany
⁷Division of Stem Cell Transplantation and Cellular Immunotherapies, University Hospital Schleswig-Holstein, Kiel, Germany
⁸Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, LMU University Hospital, LMU Munich, Munich, Germany

3:15 PM

915

One-Step Construction of Allogeneic CAR-NK Cells Preventing Rejection and Mediating Enhanced Anti-Tumor Responses

Fuguo Liu^1,2^*, Mubin Tarannum, PhD¹^*, Yingjie Zhao³^*, Yiming J Zhang²^*, James Dongjoo Ham⁴^*, Kewen Lei²^*, Yuhao Qiang²^*, Xingyu Deng¹^*, Maily Nguyen¹^*, Dinh Khanhlinh¹^*, Shaobo Yang¹^*, Alaa Kassim Ali, PhD¹, Grace Caroline Birch, PhD¹^*, Yuwen Yin²^*, Junru Cui²^*, Fangfeng Yuan²^*, Jerome Ritz, MD¹, Jianzhu Chen²^* and Rizwan Romee, MD^1,5,6

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
²Koch Institute For Integrative Cancer Research at MIT, Cambridge, MA
³Koch Institute For Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA
⁴Massachusetts Institute of Technology, Koch Institute For Integrative Cancer Research, Cambridge, MA
⁵Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁶Brigham & Women's Hospital, Boston, MA

3:30 PM

916

W-NK1 Choreographs Innate and Adaptive Immune Responses to Provide a Robust and Durable Anti-AML Response

Tom Leedom¹^*, Basia Muz, PhD, MSc²^*, Kristann Magee²^*, Jayakumar Vadakekolathu, PhD³^*, Laura Arthur, PhD⁴^*, Melissa Tran, MSc¹^*, Lena Luukkonen, BS¹^*, Nitin Mahajan, PhD, MSc, MS⁵^*, Alexander Hamil, PhD¹^*, John Muth, MSc⁶^*, Melissa M Berrien-Elliott, PhD⁷^*, Todd A Fehniger⁸, Sergio Rutella, MD, PhD, FRCPath⁹ and Jan K Davidson-Moncada, MD, PhD, MSc¹⁰

¹Wugen, San Diego
²Wugen, St Louis
³John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, United Kingdom
⁴Wugen, Saint Louis, MO
⁵Wugen, St Louis, MO
⁶Wugen, St. Louis, MO
⁷St Louis University, St Louis
⁸Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO
⁹John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, ENG, United Kingdom
¹⁰Wugen, Washington, DC

3:45 PM

917

Mesothelin Targeting IL12-Engineered CAR Memory-like NK Cells Demonstrate Promising Efficacy in Acute Myeloid Leukemia

Jieun Jang, MD, PhD^1,2, Mila Stanojevic¹^*, Sara Piccinelli, MD, PhD¹^*, Michal Sheffer, PhD¹^*, Grace Caroline Birch, PhD¹^*, Roman M. Shapiro, MD¹, Maximilian Stahl, MD³, John Koreth, MD, MBBS, PhD, DPhil¹, Catherine J. Wu, MD⁴^*, Robert J. Soiffer, MD⁵, Jerome Ritz, MD¹, Mubin Tarannum, PhD⁴^* and Rizwan Romee, MD¹

¹Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²Yonsei University College of Medicine, Seoul, South Korea
³Dana Farber Cancer Institute, Boston, MA
⁴Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁵Dana-Farber Cancer Inst., Boston, MA

4:00 PM

918

CSF1R Targeting T Cell Engaging Bispecific Antibodies Enable Safe and Efficient Immunotherapies in Acute Myeloid Leukemia

Gordon Victor Hoffmann¹^*, Adrian Gottschlich, MD^1,2,3,4^*, Johannes Sam, PhD⁵^*, Samuel Gebhardt⁵^*, Lisa Rohrbacher, MSc^2,6^*, Sayantan Nandi, PhD¹^*, Emanuele Carlini¹^*, Tobias Herold, MD^2,3, Michael von Bergwelt-Baildon, MD, PhD^2,4,7^*, Stefan Endres, MD, Prof^1,3,8^*, Marion Subklewe, MD^3,4,6,9, Peter Bruenker, PhD⁵^*, Christian Klein, PhD⁵ and Sebastian Kobold, MD^1,3,8^*

¹Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany
²Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
³German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany
⁴Bavarian Cancer Research Center (BZKF), Munich, Germany
⁵Roche Innovation Center Zürich, Pharma Research & Early Development, Zurich, Switzerland
⁶Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany
⁷germ, Munich, Germany
⁸Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany
⁹Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

703.O1.6 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Enhancing NK Cell Therapeutics